COR

Cencora Inc. (COR) | Rumor.io

Cencora

COR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,669

Bullish sentiment (50-day avg)100%

Price to earnings ratio22.6

Market capitalization58B

Earnings per share13.5

Dividend yield (TTM)0.79%

Revenue (annual)321.3B

Net income (annual)1.6B

Social

What share of all stock conversation is about COR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% -0.01

Jun 15

Cencora, Inc. (COR) is expected to be influenced by a potential US-Iran deal and subsequent energy price decrease.
A decrease in energy prices and inflation could lead to a rate cut by the Federal Reserve.
Market volatility is expected to persist despite potential positive developments.

Generated by AI

Sentiment

Of the messages about COR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	95.79% -0.65
Bearish	—	—	0% 0	4.21% +0.65

Jan 13

$COR is undervalued at around $2.7M market capitalization, with significant potential for growth in its early innings.
The company's progress on testnet phase #2, including validators, dynamic pricing, and infrastructure testing, suggests steady and improving development.
$COR's focus on decentralized AI inference and its commitment to 24/7 building and innovation make it a promising investment for the future.

Generated by AI

Topics

Of the messages about COR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	37.88%
Earnings	—	—	—	10.43%
Analysts	—	—	—	5.88%
Controversies	—	—	—	0.45%
Macro	—	—	—	20.05%
Technical Analysis	—	—	—	25.31%

Earnings· May 6

Cencora, Inc.'s Q2 FY2026 earnings report showed a slight miss on adjusted EPS, with the company reporting $4.75, compared to the estimated $4.83.
Despite the earnings miss, Cencora raised its FY2026 adjusted EPS guidance to $17.65-$17.90, and lowered its sales guidance to $334.2B-$340.6B.
The company's Q2 FY2026 results also included a $1.1B one-time remeasurement gain from the OneOncology acquisition, which inflated GAAP EPS, and a $1B buyback plan.

Analysts· Nov 16

Credit Suisse downgraded CoreSite Realty ($COR) from Outperform to Neutral and raised the price target from $158 to $170.
Raymond James downgraded CoreSite Realty ($COR) from Outperform to Market Perform.
Barclays upgraded CoreSite Realty ($COR) from Underweight to Equal-Weight.

Announcements· May 22

Cencora, Inc. (COR) has achieved a 100% success rate for NodeStats and NodeReputation on DevNet5, ensuring reliable task distribution and bringing cost-effective and scalable AI.
COR's developers, with a track record at Google, have fine-tuned infrastructure, including smarter Idle Node Detection, to keep AI sessions efficient and tasks flowing smoothly.
COR has committed over 31.78 ETH to buybacks, demonstrating long-term commitment to the ecosystem, and has also added another 2 ETH to buybacks, tightening supply and keeping tasks flowing smoothly.

Technical Analysis· Feb 27

COR is in an uptrend, according to its daily Elder chart.
The Industry is in an uptrend, which is a positive indicator for COR.
The Sector is somewhat flat but has no Red Price Bars, suggesting a neutral to positive trend.

Generated by AI

Community

Of the messages about COR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	4.88%	51.89%
Newcomers	—	100%	95.12%	48.11%

Regulars· Nov 5

Cencora, Inc. plans to invest $1 billion in its US supply chain, a move that could improve the company's operational efficiency and competitiveness in the drug distribution market.
Cencora's Q4 2025 earnings report showed an adjusted EPS of $3.84, beating estimates, and revenue of $83.73B, also exceeding expectations.
Despite the earnings beat, Cencora's revenue growth is slowing, and the company has reported a $724M impairment, signaling potential headwinds for the business.

Newcomers· Feb 27

The price of $COR has increased to $368.5 per share, prompting some users to buy in, although they wish they had entered at a lower price.
Some users are setting up price alerts for $COR, indicating they are actively following the asset's movements.
A user is part of a project called "25" and bought $COR as part of this endeavor.

Generated by AI

Cencora (NYSE:COR) has outperformed the market over the past 5 years by 8.44% on an annualized basis producing an average annual return of 20.45%. Currently, Cencora has a market capitalization of $57.98 billion.

1d agoBenzinga

Cencora appoints former Ryder CEO to board of directors

5d agoInvesting.com

Cencora Elects Ryder Systems' Robert Sanchez to Board

Cencora (COR) has elected Robert Sanchez as a new independent director on its board, effective Oct.

5d agoYahoo Finance

Cencora Elects Robert E. Sanchez to Its Board of Directors

CONSHOHOCKEN, Pa., September 25, 2026--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026.

5d agoYahoo Finance

Also Discussed

Investors talking about COR also mention

#	Name	Attention
1	ADEX - Adit EdTech Acquisition Corp.	——
2	Altimar Acquisition Corp. IIATMR	0%+0
3	CRA International, Inc.CRAI	0%new
4	Alexis Practical Tactical ETFLEXI	0%0
5	GRAY - Graybug Vision, Inc.	——
6	NFNT - Infinite Acquisition Corp.	——
7	QuantumScape CorpQS	0.03%-0.02
8	Cardinal Health Inc.CAH	0%new
9	KraneShares Public-Private AI & Technology ETFAGIX	0%0
10	Affiliated Managers Group Preferred StockMGR	0%new

Cencora Inc.

Healthcare
Medical Distribution

Cencora Inc. is a global pharmaceutical solutions company focused on the sourcing, distribution, and commercialization of medicines and healthcare products. The company supports manufacturers, pharmacies, hospitals, health systems, and other care providers through wholesale distribution, specialty pharmacy services, patient access support, and supply chain solutions. Its business also includes international pharmaceutical wholesale, global commercialization services, and logistics for temperature-sensitive therapies. Cencora serves both human and animal health markets, helping improve product availability and operational efficiency across the healthcare ecosystem. Headquartered in Conshohocken, Pennsylvania, Cencora operates as a key intermediary in the pharmaceutical supply chain, connecting drug makers with the organizations that deliver care.

Website

Location

1 West First Avenue

Conshohocken, PA, 19428-1800

United States

Social

What share of all stock conversation is about COR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% -0.01

Jun 15

Cencora, Inc. (COR) is expected to be influenced by a potential US-Iran deal and subsequent energy price decrease.
A decrease in energy prices and inflation could lead to a rate cut by the Federal Reserve.
Market volatility is expected to persist despite potential positive developments.

Generated by AI

Sentiment

Of the messages about COR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	95.79% -0.65
Bearish	—	—	0% 0	4.21% +0.65

Jan 13

$COR is undervalued at around $2.7M market capitalization, with significant potential for growth in its early innings.
The company's progress on testnet phase #2, including validators, dynamic pricing, and infrastructure testing, suggests steady and improving development.
$COR's focus on decentralized AI inference and its commitment to 24/7 building and innovation make it a promising investment for the future.

Generated by AI

Topics

Of the messages about COR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	37.88%
Earnings	—	—	—	10.43%
Analysts	—	—	—	5.88%
Controversies	—	—	—	0.45%
Macro	—	—	—	20.05%
Technical Analysis	—	—	—	25.31%

Earnings· May 6

Cencora, Inc.'s Q2 FY2026 earnings report showed a slight miss on adjusted EPS, with the company reporting $4.75, compared to the estimated $4.83.
Despite the earnings miss, Cencora raised its FY2026 adjusted EPS guidance to $17.65-$17.90, and lowered its sales guidance to $334.2B-$340.6B.
The company's Q2 FY2026 results also included a $1.1B one-time remeasurement gain from the OneOncology acquisition, which inflated GAAP EPS, and a $1B buyback plan.

Analysts· Nov 16

Credit Suisse downgraded CoreSite Realty ($COR) from Outperform to Neutral and raised the price target from $158 to $170.
Raymond James downgraded CoreSite Realty ($COR) from Outperform to Market Perform.
Barclays upgraded CoreSite Realty ($COR) from Underweight to Equal-Weight.

Announcements· May 22

Cencora, Inc. (COR) has achieved a 100% success rate for NodeStats and NodeReputation on DevNet5, ensuring reliable task distribution and bringing cost-effective and scalable AI.
COR's developers, with a track record at Google, have fine-tuned infrastructure, including smarter Idle Node Detection, to keep AI sessions efficient and tasks flowing smoothly.
COR has committed over 31.78 ETH to buybacks, demonstrating long-term commitment to the ecosystem, and has also added another 2 ETH to buybacks, tightening supply and keeping tasks flowing smoothly.

Technical Analysis· Feb 27

COR is in an uptrend, according to its daily Elder chart.
The Industry is in an uptrend, which is a positive indicator for COR.
The Sector is somewhat flat but has no Red Price Bars, suggesting a neutral to positive trend.

Generated by AI

Community

Of the messages about COR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	4.88%	51.89%
Newcomers	—	100%	95.12%	48.11%

Regulars· Nov 5

Cencora, Inc. plans to invest $1 billion in its US supply chain, a move that could improve the company's operational efficiency and competitiveness in the drug distribution market.
Cencora's Q4 2025 earnings report showed an adjusted EPS of $3.84, beating estimates, and revenue of $83.73B, also exceeding expectations.
Despite the earnings beat, Cencora's revenue growth is slowing, and the company has reported a $724M impairment, signaling potential headwinds for the business.

Newcomers· Feb 27

The price of $COR has increased to $368.5 per share, prompting some users to buy in, although they wish they had entered at a lower price.
Some users are setting up price alerts for $COR, indicating they are actively following the asset's movements.
A user is part of a project called "25" and bought $COR as part of this endeavor.

Generated by AI

Cencora

Social

Jun 15

Jan 13

Earnings· May 6

Analysts· Nov 16

Announcements· May 22

Technical Analysis· Feb 27

Regulars· Nov 5

Newcomers· Feb 27

Cencora Inc. stock outperforms competitors on strong trading day

Cencora Inc. stock outperforms competitors despite losses on the day

$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today - Cencora (NYSE:COR)

Cencora appoints former Ryder CEO to board of directors

Cencora Elects Ryder Systems' Robert Sanchez to Board

Cencora Elects Robert E. Sanchez to Its Board of Directors

Also Discussed

Cencora Inc.

Company Information

Location

Cencora Inc. stock outperforms competitors on strong trading day

Cencora Inc. stock outperforms competitors despite losses on the day

$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today - Cencora (NYSE:COR)

Cencora appoints former Ryder CEO to board of directors

Cencora Elects Ryder Systems' Robert Sanchez to Board

Cencora Elects Robert E. Sanchez to Its Board of Directors

Also Discussed

Social

Jun 15

Jan 13

Earnings· May 6

Analysts· Nov 16

Announcements· May 22

Technical Analysis· Feb 27

Regulars· Nov 5

Newcomers· Feb 27